CTLA4 and melanoma: OS curves plateaued after 3 years - akin to the pattern observed in the pooled analyses of melanoma patients treated with CTLA-4 inhibitor ipilimumab and PD-1 inhibitors nivolumab and pembrolizumab, albeit at a lower fraction [22–24].